Background Checkpoint inhibitors have shown modest activity in patients with advanced hepatocellular carcinoma (HCC). Herein, the authors report a prospective single‐institution clinical/translational phase 2 study of pembrolizumab in patients with advanced HCC and circulating biomarkers closely related to response. Methods Pembrolizumab was administered at a dose of 200 mg intravenously every 3 weeks among patients who may have developed disease progression while receiving, were intolerant...
Background There exist insufficient data characterizing patients with multiple myeloma (MM) who experienced prolonged survival. A population‐based analysis of long‐term survivors was conducted to investigate the roles of sociodemographic factors and upfront stem cell transplantation (SCT). Methods The National Cancer Data Base is a US cancer database of approximately 34 million patients from >1500 cancer centers. Patients with MM were identified using the International Classification of...
Background Curative therapy places childhood cancer survivors at increased risk for second primary malignancies (SPMs). However, there have been few population‐based attempts to characterize differences between outcomes of SPMs in childhood cancer survivors and outcomes of first primary malignancies (FPMs). Methods Clinical and demographic information about childhood cancer survivors who developed SPMs and individuals with comparable FPMs was extracted from the Surveillance, Epidemiology,...
Background Patients with anaplastic glioma (AG) harboring an isocitrate dehydrogenase mutation have potential durable survival after intensity‐modulated radiotherapy (IMRT) and chemotherapy. Understanding long‐term functioning, and the factors that have an impact on later effects, is important for decision making. Methods Consecutive patients with AG who received IMRT were reviewed with regard to 6 survivorship domains, including Eastern Cooperative Oncology Group (ECOG) performance status,...
Background Management for men aged ≤55 years with low‐risk prostate cancer (LRPC) is debated given quality‐of‐life implications with definitive treatment versus the potential missed opportunity for cure with conservative management. The objective of this study was to define rates of conservative management for LRPC and associated short‐term outcomes in young versus older men in the United States. Methods The nonpublic Surveillance, Epidemiology, and End Results Prostate with Active Surveillance/Watchful...
No comments:
Post a Comment